drug_type
RELEVANT_DRUG
intervention_type
Cell therapy (autologous gene-modified CAR T cells)
drug_description
Autologous, gene-modified T cells engineered to express an anti-CD7 chimeric antigen receptor; administered as a single infusion of 2×10^8 CAR+ T cells to target CD7-expressing malignant cells in r/r T-ALL/LBL and CD7-positive AML. Mechanism involves CAR-mediated CD3ζ/costimulatory signaling leading to MHC-independent activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity; expected on-target depletion of normal CD7+ T/NK cells (T-cell aplasia).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD7 chimeric antigen receptor. CAR binding to CD7 triggers CD3ζ and costimulatory signaling, driving MHC‑independent T‑cell activation, expansion, cytokine release, and perforin/granzyme‑mediated killing of CD7‑positive malignant cells (r/r T‑ALL/LBL and CD7+ AML), with expected on‑target depletion of normal CD7+ T/NK cells (T‑cell aplasia).
drug_name
RD13-02 CAR-T cells (anti-CD7 autologous CAR T cells)
nct_id_drug_ref
NCT05907603